NYSE:MD - MEDNAX Stock Price, Forecast & News

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

MEDNAX Inc (NYSE:MD) announced its quarterly earnings results on Thursday, February, 20th. The company reported $0.91 EPS for the quarter, beating the Zacks' consensus estimate of $0.83 by $0.08. The business had revenue of $905.38 million for the quarter, compared to analyst estimates of $900.85 million. MEDNAX had a negative net margin of 42.63% and a positive return on equity of 12.22%. MEDNAX's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.92 EPS. View MEDNAX's Earnings History.

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for MEDNAX.

MEDNAX issued an update on its first quarter earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $0.55 to $0.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.63.

11 Wall Street analysts have issued 12 month price targets for MEDNAX's shares. Their forecasts range from $18.00 to $34.00. On average, they expect MEDNAX's stock price to reach $25.82 in the next twelve months. This suggests a possible upside of 49.3% from the stock's current price. View Analyst Price Targets for MEDNAX.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Press coverage about MD stock has trended positive on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MEDNAX earned a daily sentiment score of 2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for MEDNAX.

MEDNAX saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 5,400,000 shares, a decrease of 11.2% from the January 30th total of 6,080,000 shares. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 6.7% of the company's stock are short sold. View MEDNAX's Current Options Chain.

Some companies that are related to MEDNAX include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Gilead Sciences (GILD), AbbVie (ABBV), Dominion Energy (D), Pfizer (PFE), Exxon Mobil (XOM), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), General Electric (GE) and AT&T (T).

MEDNAX's stock is owned by many different of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (6.35%), P2 Capital Partners LLC (4.63%), State Street Corp (2.59%), FMR LLC (2.02%), LSV Asset Management (1.54%) and Prudential Financial Inc. (1.52%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

MD stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Panagora Asset Management Inc., State Street Corp, Goldman Sachs Group Inc., Man Group plc, AlphaCrest Capital Management LLC and Stone Ridge Asset Management LLC. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

MD stock was bought by a variety of institutional investors in the last quarter, including P2 Capital Partners LLC, Great Lakes Advisors LLC, LSV Asset Management, Renaissance Technologies LLC, Bank of New York Mellon Corp, William Blair Investment Management LLC, Schroder Investment Management Group and Mackay Shields LLC. View Insider Buying and Selling for MEDNAX.

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MD stock can currently be purchased for approximately $17.29.

MEDNAX has a market capitalization of $1.46 billion and generates $3.51 billion in revenue each year. The company earns $-1,497,700,000.00 in net income (profit) each year or $3.14 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

The official website for MEDNAX is http://www.mednax.com/.

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]